Kolistimetatnatrium Xellia (Colistimethate Sodium)

Colistimethate sodium binds to the lipopolysaccharide layer of Gram‑negative bacterial outer membranes, disrupting membrane integrity and increasing permeability. This leads to leakage of cellular contents and bacterial cell death, providing a bactericidal effect against resistant organisms.

The dosage of Kolistimetatnatrium Xellia is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and susceptibility data. Healthcare professionals adjust the regimen to achieve optimal therapeutic outcomes.

Safety data for colistimethate sodium during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Kolistimetatnatrium Xellia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kolistimetatnatrium Xellia delivers colistimethate sodium, the same active component found in other colistin products. Its efficacy and safety profile are comparable, but formulation differences such as concentration, excipients, and packaging may influence handling, storage, and dosing preferences in clinical practice.

Kolistimetatnatrium Xellia should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. Use aseptic technique during preparation and administration to maintain sterility and ensure product stability.

The product is administered intravenously by a qualified healthcare professional. It is typically reconstituted with a suitable diluent and infused over a prescribed period, with infusion rates adjusted according to renal function and patient tolerance.

The most serious risks include nephrotoxicity, which can lead to acute kidney injury, and neurotoxicity, which may cause seizures or neuromuscular blockade. Rare but life‑threatening reactions such as anaphylaxis, severe skin reactions, and respiratory paralysis also require immediate medical attention.

Kolistimetatnatrium Xellia should be avoided in patients with known hypersensitivity to colistin or any component of the formulation, and used with extreme caution in individuals with pre‑existing neuromuscular disorders, severe renal impairment, or those receiving concurrent nephrotoxic or neuromuscular‑blocking agents.